Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Main Inclusion Criteria: * Signed and dated written informed consent * Male or female ≥18 years of age at the time of informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy \>3 months assessed during Screening * Histologically or cytologically confirmed, locally advanced or metastatic squamous NSCLC Main Exclusion Criteria: * Any antineoplastic agent (standard or investigational) within 2 weeks prior to starting trial treatment * Radiosurgery or radiotherapy for target lesions within 2 weeks prior to starting trial treatment * Prophylactic use of hematopoietic growth factors within 1 week prior to starting trial treatment * Active Central Nervous System (CNS) metastases or carcinomatous meningitis * Women who are pregnant * Women who are breastfeeding